pharma · Metastatic Lung Non-Small Cell Carcinoma · COVID-19 · OTLC
Oncotelic Therapeutics
Oncotelic Therapeutics patent portfolio — 1 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Seoul, KR HQ
2020 Founded
14 Employees
Public company Type
OTLC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Seoul, KR
- Founded
- 2020
- Employees
- 14
- Programs
- 4
- Drugs
- 3
- Patents
- 1
Oncotelic Therapeutics patents
1 pharmaceutical patents indexed for Oncotelic Therapeutics. 0 expire within 24 months.
Oncotelic Therapeutics has 1 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
Frequently asked questions
How many patents does Oncotelic Therapeutics have?
1 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Oncotelic Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.